Medigene AG: Medigene amends 2022 financial guidance
Planegg/Martinsried (10.03.2023) - The Executive Management Board of Medigene AG (Medigene, FSE: MDG1, Prime Standard), an early stage immuno-oncology platform company focusing on the discovery and development of T cell immunotherapies for solid tumors, today adjusted financial guidance for fiscal year 2022.
The company maintains its guidance on expected revenues to be approximately €30-32 million in 2022.
Research and development costs will increase from prior estimates of €12-14 million to €28-29 million. This is a result of a further write-down of €15.5 million on the drug candidate RhuDex® licensed to Dr. Falk Pharma GmbH, due to the expected termination of the phase 2 clinical study in patients with primary biliary cirrhosis (PBC) by Dr. Falk Pharma.
Estimates for earnings before interest, taxes, depreciation and amortization (EBITDA) remain unchanged and are expected at € 12-14 million.
The company estimates that it is financed into the fourth quarter of 2024 based on current planning (unchanged).
(end)
Emitter: |
Medigene AG Lochhamer Straße 11 82152 Planegg/Martinsried Germany |
Contact Person: |
Medigene PR/IR |
Phone: |
+49 89 2000 3333 01 |
E-Mail: |
|
Website: |
|
ISIN(s): |
DE000A1X3W00 (Share) |
Stock Exchange(s): |
Regulated Market in Frankfurt, Free Market in Berlin, Free Market in Dusseldorf, Free Market in Hamburg, Free Market in Hannover, Free Market in Munich, Free Market in Stuttgart, Open Market in Tradegate |
Medigene AG Stock
With 1 Buy predictions and 2 Sell predictions the community is currently undecided on Medigene AG.
With a target price of 1 € there is a slightly negative potential of -17.7% for Medigene AG compared to the current price of 1.22 €.
